Erika P. Hamilton, MD | Authors


Exploring the Rationale for OP-1250 in Advanced HR-Positive HER2-Negative Breast Cancer

January 12, 2021

Erika P. Hamilton, MD, discusses the rationale for exploring OP-1250 monotherapy in an open-label first-in-human multi center phase 1/2 study in adult patients with advanced and/or metastatic hormone receptor-positive, HER2-negative breast cancer.

Dr. Erika P. Hamilton on Difficulties of Treating Brain Metastases in Breast Cancer

February 19, 2016

Hamilton says there are currently not very many "good" drugs for treating these metastases. She adds that the mainstay for treating these metastases is usually some form of radiation therapy, such as whole brain radiation.